WENDY L DIXON
CIK 1202283 · last filed 2025-05-30
WENDY L DIXON is a corporate insider who has filed 145 SEC Form 4 insider transactions across 13 companies since 2010. The most recent filing, for ZVRA, was dated May 30, 2025. Across all open-market trades the lifetime net is −$7.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.9M across reported positions. 45 SEC filings were submitted jointly with INCYTE CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.87M
13
145
-$7.76M
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZVRA | Director | — | $12.40 | — | $0 | 3 | 2025-05-30 |
| BDTX | Director | 38,054 | $2.12 | $80.7K | $0 | 12 | 2024-04-03 |
| ARVN | Director | 9,121 | $9.39 | $85.6K | $0 | 4 | 2023-06-20 |
| ALKS | Director | 53,124 | $46.10 | $2.45M | -$1.05M | 21 | 2022-06-16 |
| IOVA | Director | — | $8.79 | — | $0 | 1 | 2022-06-14 |
| INCY | Director | 17,768 | $126.75 | $2.25M | -$6.71M | 43 | 2022-04-04 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 595 | $4.97 | $3.0K | $0 | 8 | 2021-11-17 |
| VYGR | Director | — | $3.51 | — | $0 | 5 | 2020-06-05 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 2 | 2019-06-21 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 4 | 2017-05-23 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | — | — | — | $0 | 6 | 2015-06-10 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | Director | 7,160 | — | — | $0 | 7 | 2014-03-04 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | — | — | — | $0 | 3 | 2012-06-20 |
Recent Filings
145 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-05-30 | ZVRA | Grant (A) | — | $0 | EDGAR |
| 2024-05-15 | ZVRA | Grant (A) | — | $0 | EDGAR |
| 2024-04-03 | BDTX | Grant (A) | +3,253 | $14.8K | EDGAR |
| 2023-12-15 | BDTX | Grant (A) | +4,043 | $11.0K | EDGAR |
| 2023-09-18 | BDTX | Grant (A) | +2,986 | $10.7K | EDGAR |
| 2023-06-20 | ARVN | Grant (A) | +4,121 | $0 | EDGAR |
| 2023-06-16 | BDTX | Grant (A) | +5,119 | $10.7K | EDGAR |
| 2023-05-17 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2023-05-08 | ZVRA | Grant (A) | — | $0 | EDGAR |
| 2023-03-20 | BDTX | Grant (A) | +6,437 | $10.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.